Financial Statements
for the 1st quarter of fiscal year ending March 31, 2019
(From Apr. 1, 2018 to Jun. 30, 2018)

Summary of consolidated results

JMS Co., Ltd.
Company Code No. 7702

August 8, 2018

1Highlights in Business Results(unit: JPY million)
Apr. ‐ Jun. 2017
Results

Net sales

Apr. ‐ Jun. 2018
Results

Diff.

Year– over – Year

13,24013,936695

5.3%

Operating profit

4628(17)(38.6%)

Ordinary profit

14880(67)(45.7%)

Profit attributable toowners of parent

238

22(215)(90.4%)

JPY 9.77

JPY 0.94‐‐‐‐‐‐US Dollar111.09

109.07Euro

121.08133.22Singapore Dollar

79.79

81.79

Basic earnings per share※
Exchange Rate(averageduring period)(unit: JPY)

Overseas

Japan
Sales

‐Increased sales of New Hemodialysis Machine “GC‐X01”‐Increased sales of Dysphagia related products

Increased in sales, but decreased in profit
for the 1st Quarter of FYE Mar. 2019

‐Decreased sales of Blood Bags and AV Fistula Needles

Profit‐The influence of increased sales was offset by the increase in labor cost and R&D cost, resulting in operating profit‐The addition of share of profit of entities accounted for using equity method was offset by the foreign exchange losses, resulting in ordinary profit‐A change in decreased income taxes ‐ deferred resulted in Profit attributable to owners of parent※We have conducted a share consolidation of common stock of JMS Co., Ltd. pursuant to which two (2) shares were consolidated into one (1) share effective as of October 1, 2017.
Accordingly, the “Basic earnings per share” has been calculated assuming that such share consolidation has been conducted at the beginning of the previous fiscal year.

2Summary by segment (geographical area)(unit: JPY million)

Singapore *Japan
10,2109,469■ Sales incl.
internal transaction■ Sales for third party－ Profit

4,613■ Sales incl.
internal transaction■ Sales for third party－ Profit■ Sales incl.
internal transaction■ Sales for third party－ Profit

862
759

9,439

8,670

Sales
Increased
7.8%

1901401012,350
44Apr. ‐ Jun.
2017

4,653

China

[Sales]Increased sales of New Hemodialysis Machine“GC‐X01” raised net sales.
[Ordinary Income]Despite the influence of sales increase, the increasein R&D cost by clinical trial costs for new productresulted in profit.

ProfitDecreased
26.5%

Apr. ‐ Jun.
2017

Sales
Decreased
12.0%

319

2,196

ProfitDecreased
56.0%

Apr. ‐ Jun.
2018

Sales
Increased
0.9%

Apr. ‐ Jun.
201813
Apr. ‐ Jun.
2017

331

(0.8)

ProfitDecreased by
14
million yen

Apr. ‐ Jun.
2018

[Sales]Increased sales of Safety Scalp Vein Needles
for North America market raised net sales.

[Sales]Decreased sales of Infusion Sets for Japan
market by production transfer to Philippines
reduced net sales.

[Ordinary Income]The influence of increased labor cost resulted[Ordinary Income]The influence of decreased sales and theincrease of foreign exchange losses resulted inloss.

in profit.
*This segment includes Indonesia local subsidiary.

3

Summary by segment (geographical area)(unit: JPY million)

Others *Philippines324■ Sales incl.
internal transaction－ Profit

1,899

1,968

Sales
Increased
181.3%

115105(166)
Apr. ‐ Jun.
2017

(129)

ProfitImproved by37
million yen

Apr. ‐ Jun.
2018

[Sales]Increased sales of Infusion Sets for Japan
market raised net sales.
[Ordinary Income]The influence of increased sales reduced loss.

～Product introduction～■ Sales for third party－ Profit

66

Apr. ‐ Jun.
2017

Sales
Increased
3.7%

ProfitIncreased
59.1%

Apr. ‐ Jun.
2018

*This segment includes business activity of domestic
subsidiaries, Germany, United States and South
Korea.

Hemodialysis Machines
Hemodialysis machine is a device for pulling
blood from a patient into an extracorporeal
circuit. The blood is purified by a dialyzer andreturned to the patient by the hemodialysis
machine.

4

Sales by Business Segment
Apr. – Jun. 2017

Apr. – Jun. 2018Others 2.8%

Transfusion
16.2%

5,742
5,338
4,488

Cardiovascular
7.6%(unit: JPY million)

Apr. – Jun.
2018

Infusion & Nutrition
41.2%

4,032
Dialysis
32.2%

2,388

1,123

2,255

1,057
357

Infusion & Nutrition

Dialysis

CardiovascularTransfusion

392

Others5

Sales increase or decrease (Customer's Location)
Others1.6%

Europe8.4%
North America
11.5%(unit: JPY million)
Japan
65.9%

Apr. – Jun.
2018

Asia
12.6%

142

74746

13,936(52)(215)

13,240
Increased
JPY 695 million

Apr. ‐ Jun. 2017

JapanAsia

North AmericaEuropeOthers

Apr. ‐ Jun. 2018
6Selling, General and Admin. Expenses(unit: JPY million)

3,361

25.4%

3,425

24.6%

(unit: JPY million)
Apr. ‐ Mar.
2018

Labor Cost

1,454

1,477

23

1.6%

Transport

398

401

3

0.8%

R&D

301

421

120

39.9%

Depreciation

8584(1)(1.3%)

1,121

1,040(80)(7.2%)

3,361

3,425

64

1.9%

Others
Total

Apr. ‐ Jun.
2017

Year‐over‐Year

Apr. ‐ Mar.
2017

Diff.

Apr. ‐ Jun.
20187Ordinary profit : Compared with the previous year
(unit: JPY million)

Minus factor
Apr. ‐ Jun. 2017

14858

Increase of
Gross Profit（50）

Increase of SGA

Decreased
JPY 67 million

（32）
（42）
Apr. ‐ Jun. 2018

Plus factor

Decrease ofNon‐operating profit
Impact ofExchange rate

80
The underlined figures exclude impact of exchange rate.
8Forecast for FYE Mar. 2019
(unit: JPY million)FYE Mar. 2018
ResultNet sales

FYE Mar. 2019
Forecast

Year‐over‐Year

56,52058,000

2.6%

Operating profit

573

1,000

74.3%

Ordinary profit

820

1,200

46.3%

Profit attributable toowners of parent

631

800

26.7%

JPY 25.91

JPY 32.83‐‐‐Basic earnings per share
Exchange Rate(average duringperiod)

US Dollar

110.85105Euro126.67130(unit: JPY)

Singapore Dollar

81.74

82

9

Topics※Announcement date‐Announcement of disposition of treasury shares as the stock compensation plan with transferrestrictions
Jul. 18, 2018

‐Announcement of introduction of the stock compensation plan with transfer restrictions
Mar. 18, 2018

‐Launching new product “TWIN SHIELD” , Catheter connection system
Apr. 18, 2018

‐Launching new product “ECmoVA” , Centrifugal Blood Pump System
Mar. 29, 2018

「ECmoVA」「TWIN SHIELD」

10

The Bridge to Good Health Care

The assessment figures described on this report are based on available information
at this moment, including uncertain data. Actual results may be different from the figures.

11